



## **Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference**

April 2, 2019

STAMFORD, Conn., April 02, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 18<sup>th</sup> Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 10:40 a.m. ET in New York, NY.

A live webcast of the presentation can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com). An archived webcast recording will be available on the Cara website for approximately 30 days.

### **About Cara Therapeutics**

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

### **INVESTOR CONTACT:**

Michael Schaffzin  
Stern Investor Relations, Inc.  
212-362-1200  
[michael.schaffzin@sternir.com](mailto:michael.schaffzin@sternir.com)

### **MEDIA CONTACT:**

Annie Starr  
6 Degrees  
973-415-8838  
[astarr@6degreespr.com](mailto:astarr@6degreespr.com)



Source: Cara Therapeutics, Inc.